NCCN Collaborates with AVEO and Astellas on Innovative Cancer Research

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--NCCN recently received a research grant from AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. to evaluate the role of tivozanib in the treatment of solid tumors.

Feed Date: 
February 16, 2012